Cost–effectiveness of natalizumab in multiple sclerosis

References

• Ann MR, Rudick RA. Drug insight: interferon treatment in multiple sclerosis. Nat. Clin. Pract. Neurol.2(1), 34–44 (2006).
   PubMedGoogle Scholar
• Weinshenker BG. The natural history of multiple sclerosis. Neurol. Clin.13(1), 119–146(1995).
   PubMed Web of Science ®Google Scholar
• Vukusic S, Confavreux C. Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr. Opin. Neurol.20(3), 269–274 (2007).
   PubMed Web of Science ®Google Scholar
• Boeije HR, Janssens AC. ‘It might happen or it might not’: how patients with multiple sclerosis explain their perception of prognostic risk. Soc. Sci. Med.59(4), 861–868 (2004).
   PubMed Web of Science ®Google Scholar
• Mitchell AJ, Benito-Leòn J, Gonzàlez JM, Rivera-Navarro J. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol.4(9), 556–566 (2005).
   PubMed Web of Science ®Google Scholar
• Rothwell PM, McDowell Z, Wong CK, Dorman PJ. Doctors and patients don’t agree: cross sectional study of patients’ and doctors’ perceptions and assessments of disability in multiple sclerosis. Br. Med. J.314(7094), 1580–1583(1997).
   PubMed Web of Science ®Google Scholar
• Compston A, Coles A. Multiple sclerosis.Lancet359(9313), 1221–1231 (2002).
   PubMed Web of Science ®Google Scholar
• Pugliatti M, Rosati G, Carton H et al. The epidemiology of multiple sclerosis in Europe. 13(7), 700–722 (2006).
   Google Scholar
• Hader WJ, Yee IM. Incidence and prevalence of multiple sclerosis in Saskatoon, Saskatchewan. Neurology69(12), 1224–1229 (2007).
   PubMedGoogle Scholar
• Orton SM, Herrera BM, Yee IM et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol.5(11), 932–936 (2006).
   PubMed Web of Science ®Google Scholar
• Orlewska E. Economic burden of multiple sclerosis: what can we learn from cost-of-illness studies? Expert Rev. Pharmacoeconomics Outcomes Res.6(2), 145–154 (2006).
   PubMedGoogle Scholar
• Leary SM, Thompson AJ. Primary progressive multiple sclerosis: current and future treatment options. CNS Drugs19(5), 369–376 (2005).
   PubMed Web of Science ®Google Scholar
• Rice GP, Incorvaia B, Munari L et al. Interferon in relapsing–remitting multiple sclerosis. Cochrane Database Syst Rev.4, CD002002 (2001).
   Google Scholar
• Munari L, Lovati R, Boiko A. Therapy with glatiramer acetate for multiple sclerosis. Cochrane Database Syst. Rev.1, CD004678 (2004).
   Google Scholar
• Martinelli BF, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst. Rev.4, CD002127 (2005).
   Google Scholar
• Kobelt G, Pugliatti M. Cost of multiple sclerosis in Europe. Eur. J. Neurol.12(Suppl. 1), 63–67 (2005).
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Lindgren P, Fredrikson S, Jonsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J. Neurol. Neurosurg. Psychiatry77(8), 918–926 (2006).
   PubMed Web of Science ®Google Scholar
• Sobocki P, Pugliatti M, Lauer K, Kobelt G. Estimation of the cost of MS in Europe: extrapolations from a multinational cost study. Mult. Scler.13(8), 1054–1064 (2007).
   PubMed Web of Science ®Google Scholar
• Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat. Rev. Drug Discov.4(6), 510–518 (2005).
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med.354(9), 899–910 (2006).
   PubMed Web of Science ®Google Scholar
• Yousry TA, Major EO, Ryschkewitsch C et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med.354(9), 924–933 (2006).
   PubMed Web of Science ®Google Scholar
• Panzara MA, Belcher G, Kooijmans M, Kim R, Lynn F, Bozic C. Use of natalizumab in patients with relapsing multiple sclerosis: updated safety results from TOUCH and TYGRIS. Presented at: 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Prague, Czech Republic, 11–14 October 2007.
   Google Scholar
• Hauser SL, Johnston SC. Recombinant therapeutics: from bench to bedside (if your health plan concurs). Ann. Neurol.60(5), A10–A11 (2006).
   Google Scholar
• Drummond M, O’Brien B, Stoddart G, Torrance G (Eds). Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford, UK (1997).
   Google Scholar
• Philips Z, Ginnelly L, Sculpher M et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol. Assess.8(36), III–XI, 1–158 (2004).
   PubMed Web of Science ®Google Scholar
• Johnson KP. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis. Neurologist13(4), 182–187(2007).
   PubMed Web of Science ®Google Scholar
• Ransohoff RM. Natalizumab for multiple sclerosis. N. Engl. J. Med.356(25), 2622–2629 (2007).
   PubMed Web of Science ®Google Scholar
• Rudick RA, Stuart WH, Calabresi PA et al. Natalizumab plus interferon b-1a for relapsing multiple sclerosis. N. Engl. J. Med.354(9), 911–923 (2006).
   PubMed Web of Science ®Google Scholar
• Rudick RA, Miller D, Hass S et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann. Neurol.62(4), 335–346 (2007).
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost–effectiveness in health and medicine. JAMA276(15), 1253–1258 (1996).
   PubMed Web of Science ®Google Scholar
• Kobelt G. Health economic issues in MS. Int. MS J.13(1), 17–26(2006).
   PubMedGoogle Scholar
• Ebers GC. Natural history of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry71(Suppl. 2), II16–II19 (2001).
   PubMed Web of Science ®Google Scholar
• Chilcott J, McCabe C, Tappenden P et al. Modelling the cost effectiveness of interferon b and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. Br. Med. J.326(7388), 522–528 (2003).
   PubMed Web of Science ®Google Scholar
• Orme M, Kerrigan J, Tyas D, Russell N, Nixon R. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health10(1), 54–60 (2007).
   PubMed Web of Science ®Google Scholar
• Lang DL, Lopert R, Hill SR. Use of pharmacoeconomics in prescribing research. Part 5: modelling – beyond clinical trials. J. Clin. Pharm. Ther.28(5), 433–439(2003).
   PubMed Web of Science ®Google Scholar
• Hobart J, Kalkers N, Barkhof F, Uitdehaag B, Polman C, Thompson A. Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite. Mult. Scler.10(1), 41–46 (2004).
   PubMed Web of Science ®Google Scholar
• Chiao E, Meyer K. Cost–effectiveness of disease modifying agents for the treatment of multiple sclerosis. Presented at: The Academy of Managed Care (AMCP) Educational Conference, Chicago, IL, USA (2006) (Abstract).
   Google Scholar
• Chiao E, Meyer K. Cost–effectiveness of disease-modifying drugs for the treatment of relapsing remitting multiple sclerosis. J. Manag. Care Pharm.12(7), 598–588(2006).
   Google Scholar
• Al-Sabbagh A, Papshev D. Comparative analysis of multiple sclerosis cost effectiveness models: focus on the managed care perspective.Presented at: The Academy of Managed Care Pharmacy Hosts 19th Annual Meeting & Showcase, San Diego, CA, USA April 11–14, 2007.
   Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon b-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol.39(3), 285–294 (1996).
   PubMed Web of Science ®Google Scholar
• IFNB Multiple Sclerosis Study Group. Interferon b-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. 1993. Neurology57(12 Suppl. 5), S3–S9 (2001).
   PubMedGoogle Scholar
• Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind, placebo-controlled trial. Neurology45(7), 1268–1276 (1995).
   PubMed Web of Science ®Google Scholar
• [No authors listed]. Randomised double-blind placebo-controlled study of interferon b-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon b-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet352(9139), 1498–1504 (1998).
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Bass B, Rice GP et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain112 (1), 133–146 (1989).
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain129(3), 606–616 (2006).
   PubMed Web of Science ®Google Scholar
• Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain129(3), 584–594 (2006).
   PubMed Web of Science ®Google Scholar
• Phillips CJ. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment. CNS Drugs18(9), 561–574 (2004).
   PubMed Web of Science ®Google Scholar
• Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Cost–effectiveness of interferon b-1a, interferon b-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health7(5), 554–568 (2004).
   PubMed Web of Science ®Google Scholar
• Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K. Cost-effectiveness of four immunomodulatory therapies for relapsing–remitting multiple sclerosis: a Markov model based on long-term clinical data. J. Manag. Care Pharm.13(3), 245–261 (2007).
   PubMed Web of Science ®Google Scholar
• Curtiss FR. Pharmacoeconomic modeling of drug therapies for multiple sclerosis – are we building houses on sand? J. Manag. Care Pharm.13(3), 287–289 (2007).
   PubMedGoogle Scholar
• Grima DT, Torrance GW, Francis G, Rice G, Rosner AJ, Lafortune L. Cost and health related quality of life consequences of multiple sclerosis. Mult. Scler.6(2), 91–98 (2000).
   PubMed Web of Science ®Google Scholar
• Berg J, Lindgren P, Fredrikson S, Kobelt G. Costs and quality of life of multiple sclerosis in Sweden. Eur. J. Health Econ.7(Suppl. 2), S75–S85 (2006).
   PubMedGoogle Scholar
• Pittock SJ, Mayr WT, McClelland RL et al. Change in MS-related disability in a population-based cohort: a 10-year follow-up study. Neurology62(1), 51–59 (2004).
   PubMed Web of Science ®Google Scholar
• Kappos L, Bates D, Hartung HP et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol.6(5), 431–441 (2007).
   PubMed Web of Science ®Google Scholar
• Simpson BS, Coles AJ. Rationale for cytotoxic monoclonal antibodies in MS. Int. MS J.14(2), 48–56 (2007).
   PubMedGoogle Scholar